TP53 and neoplasm: Research has focused on the design of different types of MDM2/MDMX antagonists to activate p53, and some MDM2 inhibitors have entered clinical trials targeting MDM2 to activate the p53 protein and inhibit tumor growth (Li et al., 2017; Daniele et al., 2021).